The BioIndustry Association (BIA) welcomes the Prime Minister's announcement of a coordinated life sciences strategy which could provide a foundation for the future of the bioscience sector in the UK
14 December 2011
This month’s editorial is written by Antony J. Williams and Sean Ekins. “If I have seen further than others, it is by standing upon the shoulders of giants.”Isaac Newton
09 December 2011
A new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE) compared to those treated with a sulphonylurea (SU).
06 December 2011
The Drug Discovery Oxford 2012 – “Drug discovery: a job too complex for academia or industry alone?” conference is only a month away.
05 December 2011
The European Federation of Pharmaceutical Industries and Associations (EFPIA), the voice of the research-based pharmaceutical industry in Europe, welcomes the launch of the European Commission’s new Framework for Research and Innovation: Horizon 2020.
01 December 2011
The University of Cambridge and Elan Corporation plc today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England.
28 November 2011
Celgene, one of the world’s largest developers of biopharmaceuticals has demonstrated its commitment to UK expansion with the opening of its new London headquarters, accommodating its growing numbers of UK staff and the Celgene global regulatory and drug safety teams.
23 November 2011
Biomarkers. There was a time in the not-so-distant past when simply identifying a biomarker was considered a drug discovery success. Like the low hanging fruit initially exposed by the genomic revolution, that once common view has long since disappeared. Today, the line between the bench and the clinic is becoming increasingly blurred. Translational science has become a core element of the drug discovery paradigm, and with it has come an increasing need for an integrated, multidisciplinary approach to biomarker development.
23 November 2011
As consumers and health systems move toward greater reliance on self-care, regulatory and clinical decision making should be improved through new tools to assess the unique benefits and challenges of self-care nonprescription [‘over-the-counter’, (OTC)] products, according to a new White Paper published in the peer-reviewed journal Clinical Pharmacology & Therapeutics.
16 November 2011
Pantarhei Bioscience, a specialty pharmaceutical company focusing on the development of innovative, proprietary treatments in the fields of women’s health and endocrine cancer, announces the publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB J October 5, 2011) of the results of an innovative treatment strategy for ovarian cancer, which has now been selected to appear in the Faculty of 1000 (F1000) emphasizing its significance.
15 November 2011
The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
14 November 2011
The company behind a pioneering stem cell bandage, believed to be the world’s first adult and autologous (patient’s own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK’s most successful entrepreneurs.
14 November 2011
A new educational campaign is being launched in the UK to educate people with type 2 diabetes on ‘hypoglycaemia’ and how it can be prevented and managed. The ‘Are You Running on Empty?’ campaign is collaboration between Diabetes Nursing Group, TREND, The Automobile Association (AA) and MSD Diabetes.
08 November 2011
Almac’s Diagnostics business unit today announced the publication of its stage II colon cancer recurrence signature (diagnostic test) in the Journal of Clinical Oncology.
08 November 2011
Domainex Ltd, the UK-based drug discovery company focused on speed and innovation, has been awarded a £250,000 grant by the Technology Strategy Board (TSB), the UK’s national innovation agency, to help support the development of a new drug for the treatment of several common cancers.
01 November 2011
A comprehensive database developed by King’s College London researchers that features the chemical components found in traditional Chinese medicines has been released to market this month, enabling researchers to explore age-old remedies in the search for tomorrow’s new drugs.
21 October 2011
DiaGenic reports preliminary positive findings from the collaborative R&D project with Pfizer Inc. where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring Alzheimer’s disease.
19 October 2011
Diabetes is the theme of this month’s edition of Drug Discovery Today’s Editor’s Choice newsletter. According to the latest data published by the World Health Organization (WHO) approximately 346 million people worldwide are living with diabetes today. If left untreated, chronic hyperglycemia can lead to several macrovascular and microvascular diabetic complications. In spite of the epidemic proportions, exploding healthcare costs, and the great impact this disease has on patients, health care providers, health care systems and insurers, to date, no cures have been identified yet.
18 October 2011
Roche announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease.
12 October 2011
Six new genetic variants will help identify diagnostic markers and drug targets for the 55 million Asian’s affected.
11 October 2011